{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:00:08Z","timestamp":1760403608705,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001837","name":"Eesti Teadusfondi","doi-asserted-by":"publisher","award":["7034","SF0180125s08","SF0182590As03"],"award-info":[{"award-number":["7034","SF0180125s08","SF0182590As03"]}],"id":[{"id":"10.13039\/501100001837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.euroneuro.2012.08.011","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T18:00:27Z","timestamp":1346263227000},"page":"645-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers"],"prefix":"10.1016","volume":"23","author":[{"given":"Innar","family":"T\u00f5ru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Maron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mait","family":"Raag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veiko","family":"Vasar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakov","family":"Shlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2012.08.011_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-1781(96)02948-4","article-title":"Emotional and cognitive factors associated with response to CCK-4 in healthy volunteers","volume":"66","author":"Aluoja","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/080394899427692","article-title":"Development and psychometric properties of the Emotional State Questionnaire, a self-report questionnaire for depression and anxiety","volume":"53","author":"Aluoja","year":"1999","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib3","series-title":"Serotonin and Sleep: Molecular Functional and Clinical Aspects","first-page":"569","article-title":"The effects of antidepressant drugs and 5-HT1A agonists on human sleep","author":"Argyropoulos","year":"2008"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s002130100729","article-title":"Low-dose citalopram as a 5-HT neuroendocrine probe","volume":"155","author":"Attenburrow","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1192\/bjp.172.6.465","article-title":"Serotonin and panic","volume":"172","author":"Bell","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/026988110201600116","article-title":"Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine","volume":"16","author":"Bell","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-002-1149-4","article-title":"Acute citalopram administration produces correlated increases in plasma and salivary cortisol","volume":"163","author":"Bhagwagar","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","article-title":"The use of analogue scales in rating subjective feelings","volume":"47","author":"Bond","year":"1974","journal-title":"Br. J. Psychol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1991.01810310021005","article-title":"Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioural findings","volume":"48","author":"Bradwejn","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib10","first-page":"962","article-title":"Study of the replication of action of cholecystokinin in panic disorders","volume":"92","author":"Bradwejn","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1176\/ajp.151.2.261","article-title":"Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients","volume":"151","author":"Bradwejn","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1749-6632.1994.tb44075.x","article-title":"The cholecystokinin hypothesis of anxiety and panic disorder","volume":"713","author":"Bradwejn","year":"1994","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/713783681","article-title":"Cholecystokinin and panic disorder: past and future clinical research strategies","volume":"234","author":"Bradwejn","year":"2001","journal-title":"Scand. J. Clin. Lab. Invest. Suppl."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/026988119100500414","article-title":"5-HT and mechanisms of defence","volume":"5","author":"Deakin","year":"1991","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0893-133X(98)00074-8","article-title":"Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans","volume":"20","author":"Depot","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.farmac.2005.01.002","article-title":"Liquid chromatographic-mass spectrometric method for the determination of fluoxetine and norfluoxetine in human plasma: application to clinical study","volume":"60","author":"Djordjevic","year":"2005","journal-title":"Il Farmaco"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00213-007-0738-7","article-title":"Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteer within a proof-of-concept study","volume":"192","author":"Eser","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00702-008-0047-2","article-title":"Impact of state and trait anxiety on the panic response to CCK-4","volume":"115","author":"Eser","year":"2008","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib19","first-page":"76","article-title":"Diagnosis and rating of anxiety","author":"Hamilton","year":"1969","journal-title":"Br. J. Psychiatry (Special publication)"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib20","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jpsychires.2010.04.004","article-title":"CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks","volume":"44","author":"Hinkelmann","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0924-977X(01)00100-6","article-title":"Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors","volume":"11","author":"Kasper","year":"2001","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jpsychires.2008.09.001","article-title":"The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype","volume":"43","author":"Kellner","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/0006-3223(95)00479-3","article-title":"Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers","volume":"40","author":"Koszycki","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2005-837768","article-title":"Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges","volume":"38","author":"Kronenberg","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib25","first-page":"81","article-title":"Influences of the menstrual cycle and premenstrual dysphoric disorder on the response to CCK-4","volume":"20","author":"Le Melledo","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/0269881104042619","article-title":"The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers","volume":"18","author":"Maron","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/15622970410029927","article-title":"Association between Seotonin-related Genetic Polymorphisms and CCK-4-induced Panic Attacks with or without 5-hydroxytryptophan Pretreatment in Healthy Volunteers","volume":"5","author":"Maron","year":"2004","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pscychresns.2003.10.004","article-title":"Reduced brain serotonin transporter binding in patients with panic disorder","volume":"132","author":"Maron","year":"2004","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.npp.1300880","article-title":"Serotonin function in panic disorder: important, but why?","volume":"31","author":"Maron","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neulet.2008.09.052","article-title":"Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers","volume":"446","author":"Maron","year":"2008","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/mp.2009.145","article-title":"Advances in molecular genetics of panic Disorder","volume":"15","author":"Maron","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0269881110389207","article-title":"Gender differences in brain serotonin transporter availability in panic disorder","volume":"25","author":"Maron","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"193","author":"Nash","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1523\/JNEUROSCI.4921-03.2004","article-title":"Reduced serotonin type 1A receptor binding in panic disorder","volume":"24","author":"Neumeister","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib34","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1176\/appi.ajp.158.12.1989","article-title":"An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder","volume":"158","author":"Otto","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ajmg.b.30035","article-title":"Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder","volume":"129B","author":"Perna","year":"2004","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib36","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/sj.npp.1300822","article-title":"Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene","volume":"30","author":"Perna","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00213-002-1316-7","article-title":"Pentagastrin test for anxiety-psychophysiology and personality","volume":"166","author":"Radu","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0197-0186(93)90025-Z","article-title":"Release of cholecystokinin in the central nervous system","volume":"22","author":"Raiteri","year":"1993","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib40","doi-asserted-by":"crossref","unstructured":"Rosen, A., Franck, J., Brodin, E., 1995. Effects of acute systemic treatment with the 5-HT-uptake blocker alaprocalate on tissue levels and release of substance P in rat periaquaductal grey. Neuropeptides 28, 317-324","DOI":"10.1016\/0143-4179(95)90096-9"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1037\/0021-843X.109.2.308","article-title":"Evaluating gene x psychological risk factor effects in the pathogenesis of anxiety: a new model approach","volume":"109","author":"Schmidt","year":"2000","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib42","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0269881104047283","article-title":"The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder","volume":"18","author":"Schruers","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib43","first-page":"22","article-title":"The mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib44","first-page":"332","article-title":"Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine responses to cholecystokinin tetrapeptide challenge in patients with panic disorder","volume":"22","author":"Shlik","year":"1997","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib45","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4088\/JCP.v64n1107","article-title":"Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Stahl","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib46","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/NDT.S965","article-title":"The therapeutic potential of escitalopram in the treatment of panic disorder","volume":"3","author":"Townsend","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00213-006-0351-1","article-title":"Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram","volume":"186","author":"T\u00f5ru","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.psychres.2010.04.003","article-title":"Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers","volume":"178","author":"T\u00f5ru","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2012.08.011_bib49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002130050201","article-title":"Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks","volume":"129","author":"van Megen","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(01)00266-4","article-title":"Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4)-induced panic in healthy volunteers","volume":"25","author":"Zwanzger","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2012.08.011_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.npp.1300131","article-title":"Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study","volume":"28","author":"Zwanzger","year":"2003","journal-title":"Neuropsychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12002295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12002295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:21Z","timestamp":1760377821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12002295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0924977X12002295"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.08.011","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of 6-week treatment with escitalopram on CCK-4 challenge: A placebo-controlled study in CCK-4-sensitive healthy volunteers","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}